AlphAIalphai — Financial news for AI agents
Simply Wall StreetMAY 113 min read$CDXS

US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results

Analysts have re-evaluated Codexis, Inc. (CDXS) after its latest quarterly results, which showed stronger-than-expected revenues of US$15m and lower losses per share at US$0.10. Despite an improved sentiment regarding future losses, the consensus price target has been reduced by 7.1% to US$6.58 due to ongoing profitability concerns and an anticipated revenue decline of 5.0% in 2026, contrasting with industry growth.

Original reporting
Simply Wall Street · Simply Wall St
Published May 11, 2026, 12:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 11, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results — source image
Source · Simply Wall Street
Decision brief

The 30-second read

$CDXSNeutralMed
01

Why it matters

Despite revenue strength, ongoing profitability issues and revenue decline forecasts have led analysts to lower their price targets, creating a cautious outlook.

02

Market read

The news primarily impacts investors and traders focusing on biotech stocks, especially those with recent earnings reports and profitability concerns.

03

What to watch

Potential upcoming catalysts such as new product launches or strategic partnerships that could offset profitability concerns and support stock recovery.

Timing: short-term (next 1-3 months)

Background

Codexis, Inc. reported quarterly revenues of US$15 million with losses per share reduced to US$0.10, indicating operational improvements.

Company-level read

Ticker impact

$CDXSNeutralMedium confidence
Context

Primary focus of the news, as it discusses recent analyst evaluations and future outlook.

Expected impact

Potential short-term price decline of approximately 5-7%, aligning with the reduction in target price and profitability worries.

Evidence & confidence

The analysis is based on recent earnings data and analyst revisions, but market reactions can be influenced by broader factors and investor sentiment.

Market effects

Sector

Potential cautious sentiment in the biotech and pharmaceutical sectors due to profitability concerns.

Regional

Limited; primarily affects US-based biotech stocks.

Global

Low; specific to company and sector, with minimal global market impact.

Counterpoint

What could challenge this read

The strong revenue performance and reduced losses may signal underlying operational improvements, potentially leading to a positive re-evaluation by the market in the medium term.

Key entities

  • Company
    Codexis, Inc.

    A biotechnology company focusing on enzyme engineering and biocatalysis.

  • Market Participants
    Analysts

    Financial analysts revising target prices based on recent earnings.

Read at source← All news

Related articles

JUL 23
$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

SEC EDGAR 8-K2 min
AUG 9
$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

baystreet.ca3 min
AUG 9
$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

tradearabia.com3 min
AUG 9
$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

globes.co.il4 min
AUG 9
$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

ua.news5 min